Bone Health & Immobilization Osteoporosis After SCI

Why Bone Loss After SCI Is Different from Age-Related Osteoporosis

Age-related osteoporosis develops gradually over decades. Bone loss after spinal cord injury begins within days of the injury and accelerates at a pace that has no parallel in the general population. By the time most people with SCI leave inpatient rehabilitation, their bones below the injury level are already measurably weaker than when they arrived [1].

This condition, called immobilization osteoporosis, affects bone that is no longer bearing weight or receiving muscle contraction. After SCI, this takes a more severe form known as sublesional osteoporosis (SLOP), where bone loss targets areas below the level of injury while leaving bone above the injury relatively intact. Think of bone as a living tissue that constantly rebuilds itself, similar to a road crew that fills potholes and repaves surfaces based on traffic patterns. After SCI, the crew below the level of injury stops receiving work orders. Without signals from weight-bearing and muscle contraction, the repair crew stops showing up, but the road still deteriorates. Potholes deepen, surfaces crack, and there is no one left to fill them [2][3].

Four forces converge to drive this loss [3][4]:

1. Loss of weight-bearing and muscle force (sometimes called mechanical unloading). Without standing, walking, or strong muscle contractions, bone cells stop receiving the signals that tell them to maintain or rebuild bone. This is the primary driver.
2. Disrupted nerve signals that normally regulate how fast bone is broken down and rebuilt. The nervous system plays a direct role in bone turnover (the continuous cycle of building new bone and breaking down old bone), and SCI severs that connection below the injury level.
3. Inflammatory molecules that accelerate bone breakdown. The body's inflammatory response after SCI tips the balance toward bone destruction.
4. Hormonal shifts including testosterone decline and vitamin D deficiency, both of which are common after SCI and both of which independently accelerate bone loss.

This combination makes SCI bone loss fundamentally different from the gradual decline that aging produces.

That speed is part of what makes SCI bone loss so dangerous. Most of the damage happens in the first year.

How Fast Bone Loss Happens After Spinal Cord Injury

The numbers from clinical studies are striking. In the first year after injury, bone mineral density (BMD) at paralyzed sites drops at roughly 4% per month in areas rich in trabecular (spongy) bone [1]. Trabecular bone, concentrated around the knee and at the ends of long bones, has the highest surface area exposed to the blood supply, which is why it disappears fastest.

The First Year After Injury

A 2023 peripheral quantitative CT (pQCT) study by Abdelrahman and colleagues tracked 13 people from 5 weeks after SCI through the first year. The distal femur lost up to 52% of its density. The proximal tibia lost up to 70% [5]. A separate 12-month study of 35 patients with recent complete SCI found that 59% met the clinical threshold for osteoporosis on a bone density scan (a T-score of -2.5 or worse) within the first year alone [6]. These are losses that would take decades to accumulate in someone who can walk.

Does Bone Loss Ever Stop?

Whether bone loss plateaus after the acute phase remains an open question. Cross-sectional data from 89 men with motor-complete SCI suggested that new steady states may emerge at 3 to 8 years depending on the skeletal site [2]. But longitudinal studies paint a more concerning picture. Cirnigliaro and colleagues at the VA demonstrated that bone continues to decline progressively into the second decade after injury [7]. The most compelling evidence comes from a study of identical twins in which one twin had SCI. The twin injured 7 years earlier had hip BMD at 59.5% of the uninjured sibling. By 20 years post-injury, the other twin's hip BMD had decreased to just 36.2% compared to the uninjured twin [8][9]. Screening and treatment are lifelong concerns, not just first-year priorities.

Injury completeness is the strongest predictor of severity. People with motor-complete injuries (AIS A, the most severe classification on the American Spinal Injury Association impairment scale) face the most aggressive bone loss, with one study calculating a fracture risk more than four times higher than those with incomplete injuries [6].

Understanding what drives this loss helps explain why standard osteoporosis treatments sometimes miss the mark for people with SCI.

What Drives Bone Loss After Paralysis

Four overlapping mechanisms strip bone from paralyzed limbs. Each one would cause bone loss on its own. Together, they create the fastest form of osteoporosis documented in humans.

Mechanical Unloading

Bone responds to the forces placed on it. Every time a person stands, walks, or contracts a muscle, the resulting strain signals bone cells (osteocytes) to maintain or add mineral. After SCI, paralyzed limbs no longer bear weight or generate strong muscle contractions. Osteocytes deprived of these signals begin directing the breakdown of surrounding bone. This is the primary driver of immobilization osteoporosis and the reason the condition is named for the loss of movement rather than the loss of hormones or aging [2][3].

Nerve Signals, Inflammation, and Hormones

The molecular pathways that regulate bone turnover go haywire after SCI. The RANKL/OPG system acts like a thermostat for bone demolition. RANKL tells the body to activate cells that tear down bone. OPG tells it to stop. After SCI, the thermostat gets stuck: RANKL stays high and OPG drops, so the signal to demolish bone never shuts off [10]. Gifre and colleagues documented elevated RANKL levels correlating directly with the magnitude of hip BMD loss at six months post-injury [10].

Another molecular player, sclerostin, adds complexity. Sclerostin is a protein released by osteocytes that blocks bone formation. It spikes in the first few years after SCI, then paradoxically drops as the osteocyte population itself shrinks [11][12]. This pattern has implications for a newer class of drugs (discussed in the medications section below) designed to block sclerostin.

Hormonal disruption compounds the damage. A study of 243 men with chronic SCI found that 46% had low testosterone, with levels declining 0.6% per year compared to 0.4% in the general population [13]. A meta-analysis of 13 studies totaling nearly 2,000 SCI patients found that 81.6% had insufficient vitamin D levels and 52.5% were frankly deficient [14]. These deficits accelerate bone resorption even as the other mechanisms are already driving rapid loss.

All of this bone loss has real consequences. Fractures after SCI are more common than most people realize, and they carry risks that go well beyond what a broken bone means for someone who can walk.

Fracture Risk and What a Broken Bone Means After SCI

Where and How Often Fractures Happen

Between 25% and 50% of people with traumatic SCI will sustain a fragility fracture during their lifetime, with an annual incidence of about 2 fractures per 100 patient-years [15][16]. Fractures cluster around the knee: distal femur, proximal tibia, and proximal femur each account for roughly 27-28% of cases [17]. More than 82% of all limb fractures in the SCI population occur in the legs [18].

Compared to the general population, the risk is staggering. Vestergaard and colleagues found an overall fracture relative risk of 2.0 in SCI (meaning they are twice as likely to experience a fracture than non-SCI), but for femur fractures specifically, the relative risk climbed to 23.4 [19]. Garland established fracture thresholds at the knee: fractures begin occurring below 0.78 g/cm² (representing 36% loss from normal) and the risk peaks below 0.49 g/cm² (57% loss) [20].

Why SCI Fractures Are Medical Emergencies

A broken bone after SCI is not the same injury it would be for someone who walks. Carbone and colleagues studied more than 12,000 male veterans with SCI and found that a lower extremity fracture increased mortality risk by 3.42 times in men over 50 [16]. The complications that follow fracture are severe: among fracture nonunions (when the bone does not heal), one-third develop pressure injuries from the immobilization, 13% develop osteomyelitis (a serious bone infection), and roughly one in four require amputation [21].

Fracture presentation is notoriously tricky in SCI. Because sensation below the injury is reduced or absent, fractures are frequently painless. A person may notice swelling, warmth, or redness in a limb and assume it is a blood clot or skin infection. In people with injuries at T6 and above, a fracture below the neurological level can trigger autonomic dysreflexia (AD), a sudden and dangerous spike in blood pressure, as the presenting sign [22].

Medications That Raise Fracture Risk

Several medications commonly prescribed after SCI independently accelerate bone loss. Researchers measure this using a hazard ratio (HR), which compares the fracture risk in people taking a medication to the risk in people who are not. An HR of 1.82 means the risk is 82% higher. Among commonly prescribed medications, opioids carry the highest risk (HR 1.82), followed by heparin (HR 1.48), benzodiazepines (HR 1.45), and anticonvulsants (HR 1.35) [18][16]. One potentially protective finding: thiazide diuretics were associated with a 25% reduction in lower extremity fracture risk, a strategy that may be underused in SCI care [18].

This is not a reason to stop taking prescribed medications. It is a reason to ask your prescriber whether bone-safe alternatives exist and whether a bone-protective medication should be part of your plan.

Given how high fracture risk runs, catching bone loss early matters. But the standard bone density test most doctors order can actually hide the problem.

Getting the Right Bone Density Test

Why Spine DXA Misses the Problem

Ordering a spine DXA for someone with SCI is like checking the roof of a house when the foundation is crumbling. The roof may look fine. The foundation is where the danger is.

Two types of bone density scans exist: DXA (dual-energy X-ray absorptiometry), which is widely available and used in most clinics, and QCT (quantitative computed tomography), which provides a three-dimensional measurement but is less commonly available. In the spine, these two scans can give dramatically different results after SCI. Liu and colleagues found that at the same lumbar vertebrae in SCI patients, QCT Z-scores averaged -2.4 (severely low) while DXA Z-scores averaged +1.3 (apparently normal) [23]. The DXA readings were falsely reassuring because degenerative changes and positioning artifacts inflated the numbers. A 2024 analysis confirmed this: 93% of lumbar DXA scans in SCI patients contained at least one source of error, averaging 5.5 errors per scan [24].

At the hip, a different problem can occur. Heterotopic ossification (HO), which is abnormal bone growth in the soft tissues around joints, was found in 18% of SCI patients in one study and significantly elevated BMD readings at all hip regions [25]. This means even hip DXA scans can be misleading if HO is present. Scan availability varies by location, and most people will only have access to DXA. The key is scanning at the right sites (hip and knee, not the spine) and having a provider who understands these SCI-specific limitations.

Where to Scan and When to Start

A few terms to understand when reading scan results: a T-score compares your bone density to a healthy 30-year-old of the same sex (a T-score of -2.5 or lower means osteoporosis). A Z-score compares your density to others your age. Precision (RMS-CV) measures how consistent a scan site is when tested repeatedly, with lower numbers meaning more reliable results.

R² is a statistical measure of how well one value predicts another, on a scale of 0 to 1. An R² of 0.65 means proximal tibia BMD explains about 65% of the variation in hip T-scores, making it a useful predictor. HO = heterotopic ossification (abnormal bone growth in soft tissue around joints). RMS-CV = root mean square coefficient of variation, a measure of scan precision.

The Screening Gap

Despite clear guidelines, most SCI patients are not getting the right scans. A VA survey found that only 54% of prescribing practitioners ordered any DXA scan for their SCI patients, and of those who did, only 8 scanned the knee [27]. An international survey of SCI professionals confirmed that 50% still scanned the lumbar spine and only 3.7% used DXA at the knee [28]. If your bone density has only been checked at the spine, the results may be hiding significant bone loss around your knee.

Once bone loss is confirmed, the question becomes what to do about it. Several medications have been tested specifically in the SCI population, and the results vary depending on the skeletal site.

Medications for Bone Loss After SCI

No single medication protects every skeletal site equally after SCI. The choice between drugs depends on which bones are most at risk, how long ago the injury occurred, and whether the person can commit to long-term therapy.

Denosumab (Prolia)

Denosumab is the only medication that has demonstrated effectiveness at the fracture-prone knee. In a randomized controlled trial of 18 people with subacute SCI, denosumab (60 mg every 6 months) preserved distal femur BMD over 18 months while the placebo group lost dramatically. Every person receiving placebo lost more than 10% at the hip, distal femur, and proximal tibia, with six of eight losing more than 20% [29]. The catch: when denosumab is stopped, bone loss resumes at rates comparable to untreated patients, essentially returning to where they would have been without treatment [30]. Stopping denosumab without a follow-up plan is like letting go of a rope partway up a climb. The bone you held on to disappears quickly once the drug clears. In practice, providers typically transition patients to an oral bisphosphonate (such as alendronate) and taper down gradually rather than stopping abruptly, which can help preserve some of the gains [30].

Zoledronic Acid (Reclast)

Zoledronic acid protects the hip effectively. A 60-person RCT in acute SCI showed 12-month total hip loss of only -2.2% with ZOL versus -12.8% with placebo [31]. A CT substudy predicted that femoral strength declined 9.6% with ZOL versus 24.6% without it [32]. The advantage of ZOL is its dosing: a single annual IV infusion that remains in bone for years. The limitation: the longest SCI follow-up study (POPSCI, 4 years) described "disappointing" results at the knee despite good hip outcomes [33].

Alendronate (Fosamax)

Alendronate works best when started early. A 2022 RCT initiated 70 mg weekly alendronate within 8 weeks of acute SCI and found total hip loss of only -2.7% versus -22.8% in controls [34]. An earlier trial confirmed benefit at the distal tibia over 24 months [35]. As an oral medication, alendronate offers convenience, but GI side effects and the need to sit upright for 30 minutes after dosing can pose challenges for some people with SCI.

Risedronate (Actonel)

Risedronate is another oral bisphosphonate in the same drug class as alendronate. It has been studied in other forms of osteoporosis and is sometimes prescribed after SCI, though less SCI-specific trial data exists compared to alendronate and zoledronic acid. Like alendronate, it requires sitting upright after dosing and can cause GI side effects. It is available in daily, weekly, and monthly oral dosing formats.

Romosozumab and the Sclerostin Paradox

Romosozumab (Evenity) blocks sclerostin, a protein that suppresses bone formation. The first SCI trial (12 women with chronic injuries) produced encouraging results at some sites: lumbar spine BMD increased 10.2%, total hip increased 4.2%, and predicted hip strength increased 20.3%. But at the distal femur and proximal tibia, the sites that fracture most often in SCI, there was no significant improvement [36]. The likely reason: sclerostin is already depleted at chronically unloaded bone sites because so many osteocytes have been lost [12]. Three ongoing clinical trials are testing whether starting romosozumab earlier and following it with denosumab can overcome this limitation [37].

Timing Matters More Than Drug Choice

Across all studies, one finding is consistent: early treatment dramatically outperforms delayed treatment. Once the trabecular architecture of bone has been destroyed, medications can slow further loss but cannot rebuild what is gone. Bone-protective medication conversations belong in acute rehabilitation, not years later when a scan finally reveals damage [29][31][34].

Medication alone tells only part of the story. Exercise-based approaches, especially when combined with drug therapy, add a dimension that pills and infusions cannot provide on their own.

Exercise, FES, and Non-Drug Approaches

FES Cycling and Rowing

Functional electrical stimulation (FES) delivers controlled electrical pulses to paralyzed muscles, producing contractions strong enough to pedal a cycle or drive the leg motion in an adapted rowing machine. A 12-month FES cycling study with sessions 3-4 times per week produced a 14.4% increase in trabecular BMD at the distal femur [38]. But those gains require consistency. When one study reduced FES frequency from three times weekly to once weekly, BMD returned to baseline within six months [39]. The 2022 PVA Clinical Practice Guideline recommends FES protocols that produce strong visible contractions against resistance, lasting at least 30 minutes per session, 3-5 days per week, for a minimum of one year [40].

Why Combination Therapy Works Better

Neither exercise nor medication alone does what the combination achieves. Morse and colleagues randomized 20 people with chronic SCI to FES-rowing plus a single dose of zoledronic acid or FES-rowing alone. The combination group gained cortical bone volume and thickness at the knee while the exercise-only group continued losing bone. A follow-up analysis found that predicted fracture strength at the distal femur increased 4.6% with the combination but decreased 13.9% with rowing alone [41][42].

Standing, Exoskeletons, and Vibration

Standing frames offer modest benefit. One study found that standing at least one hour daily reduced first-year leg BMD loss to -19.6% compared to -24.0% in non-standers. Statistically significant, but clinically small [43]. Exoskeletons carry fracture risk without proven bone benefit: two fractures during ReWalk training were reported in a case series, with an estimated 3.4% fracture incidence across exoskeleton programs [44]. Whole-body vibration produced no significant BMD change in the only SCI-specific RCT [45]. None of these approaches are currently recommended as standalone bone health interventions.

Vitamin D and calcium come up in almost every conversation about bone health. The research on their role in SCI is more complicated than most people expect.

Vitamin D, Calcium, and Nutrition

Nearly Everyone with SCI Is Vitamin D Deficient

A meta-analysis of 13 studies encompassing nearly 2,000 people with SCI found that 81.6% had insufficient vitamin D levels (below 30 ng/mL) and 52.5% were outright deficient (below 20 ng/mL) [14]. Contributing factors include limited sun exposure from spending more time indoors, reduced skin surface area exposed to sunlight while seated, and decreased dietary intake. Hummel and colleagues found that the threshold for optimal vitamin D in SCI may need to be higher than the standard clinical cutoff, with benefits observed above 94 nmol/L [46].

But Supplementation Alone Does Not Restore Bone

The VitD-SCI randomized controlled trial (2025) settled a long-standing question. Forty-two participants with chronic SCI received placebo, medium-dose, or high-dose vitamin D3 for 12 months. The result: no effect on bone mineral density at any measured site, including the radius, femoral neck, distal femur, and proximal tibia [47]. Vitamin D deficiency should be corrected because it affects muscle function, immune health, and other systems. But it does not replace the need for bone-specific medications.

Calcium and Kidney Stone Risk

Calcium supplementation in SCI requires caution. Hypercalciuria (excess calcium in the urine) begins within 10 days of injury, peaks at 1 to 6 months, and can reach 2 to 4 times non-SCI levels as bone rapidly breaks down and releases its mineral content.

Kidney stone incidence in SCI runs at 16.6% based on a meta-analysis of more than 64,000 patients [48]. Hypercalcemia is less common but occurs primarily in young males with cervical complete injuries during the first 6 months [49]. Adequate dietary calcium is still important, but high-dose calcium supplements may increase stone risk without meaningfully slowing bone loss.

Bone health does not exist in isolation. It connects to kidney stones, pressure injuries, medication side effects, and even spasticity management. Those connections matter for daily decision-making.

Connected Complications and Living with SCI Bone Health

Heterotopic Ossification vs. Osteoporosis

SCI produces a paradox: skeletal bone dissolves while abnormal bone can form in the soft tissues around joints. heterotopic ossification (HO) and osteoporosis are opposite processes happening in the same person. HO commonly affects the hips, knees, and elbows, causing swelling and reduced range of motion that can mimic a fracture. Critically, HO deposits also inflate DXA readings at the hip, masking underlying osteoporosis on the very scans intended to detect it [25].

Kidney Stones, Transfer Safety, and Daily Life

The rapid bone breakdown that follows SCI floods the bloodstream with calcium, contributing to the spike in kidney stones during the first six months after injury. This creates a direct link between bone health and the bladder management challenges already familiar to most people with SCI. Safe transfer techniques matter too: many SCI fractures occur during transfers, range-of-motion exercises, or falls from a wheelchair. Learning to recognize fracture signs (unilateral swelling, warmth, limb shortening, unexpected autonomic dysreflexia) can prevent delayed diagnosis.

Learn more about bladder management and kidney health after SCI in our neurogenic bladder guide →

What the Guidelines Recommend

The 2022 PVA Consortium Clinical Practice Guideline is the most current SCI-specific bone health recommendation. Its key points, translated to patient language [40]:

• Get your bone density checked at the hip and knee (not the spine) as soon as you are medically stable.
• Correct vitamin D deficiency.
• Discuss bone-protective medication early, ideally during your initial rehabilitation.
• Pursue FES-based exercise if accessible.
• If you sustain a fracture, insist on interprofessional care that addresses the secondary complications (pressure injuries, DVT, deconditioning) alongside the bone injury itself.

The ISCD and PVA guidelines agree on the most important points: do not rely on spine DXA, start screening early, FRAX is not valid for SCI, and treatment should begin before fractures occur rather than after [26][40]. The SCI-FX fracture risk score, developed by Craven and colleagues in 2023, represents the first SCI-specific prediction tool, incorporating prior fracture history, years post-injury, motor completeness, and use of benzodiazepines and opioids [15]. It still requires validation in larger populations but marks an important step toward individualized risk assessment.